Beta Drugs is one of the leading players in the domestic oncology space

Discussion in 'Latest Brokerage Stock Buy-Sell Reports' started by Vidhi Khanna, Sep 9, 2023.

Tags:
Previous Thread Next Thread
Loading...
  1. Vidhi Khanna

    Vidhi Khanna Active Member Staff Member

    Joined:
    Mar 19, 2015
    Messages:
    580
    Likes Received:
    55
    BETA DRUGS is well placed to capitalise on growth opportunities in the oncology drugs segment. It has a healthy Balance Sheet. Average RoE in past three years is 24%. P/E ratio is 15x. Revenue/earnings CAGR of 26%/33% over FY23–26 is expected. TP is Rs 1325

    Download research report

    [​IMG]
     
    Vidhi Khanna, Sep 9, 2023
    #1
Previous Thread Next Thread
Loading...
Loading...
Similar Threads
  1. priya agrawal

    Concept of alpha beta in risk analysis of a security.

    priya agrawal, Jul 11, 2016, in forum: Stock Picks Of Wizards
    Replies:
    0
    Views:
    979
    priya agrawal
    Jul 11, 2016
  2. Anish

    Mangalam drugs

    Anish, Dec 2, 2015, in forum: Ask A Query About Your Stock Picks And Portfolio
    Replies:
    1
    Views:
    1,110
    kharb
    Dec 2, 2015